 |
市场调查报告书
商品编码
1378706
谵妄管理的兴奋市场：依药物类型、给药途径、配销通路和地区划分Agitation in Delirium Management Market, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
价格
简介目录
到 2023 年，谵妄管理中的躁动的全球市场规模预计为 2.372 亿美元，预计在预测期内（2023-2030 年）年复合成长率为 4.6%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2022年 | 2023年市场规模 | 2.372 亿美元 |
| 实绩资料 | 2018-2021 | 预测期 | 2023-2030 |
| 预测期年复合成长率 | 4.60% | 2030年市场规模预测 | 3.249 亿美元 |
谵妄通常与多种疾病有关，需要多种药物治疗。早期发现和及时治疗可以降低患者发病率、住院时间、医疗费用和死亡率。英国註册的为老年人提供护理和临终关怀的机构玛丽居里在其网站上表示，许多患者在生命的最后几天出现谵妄，导致烦躁不安，据说会导致懒惰。这有时被称为末期不安或末期激动。第一代抗精神病药物是谵妄控制患者躁动的第一线治疗药物，其次是第二代抗精神病药物和苯二氮平类药物。谵妄是心理能力的显着改变。你的思绪变得混乱，你失去了对周遭环境的认知。谵妄通常会在数小时至数天内迅速发展。谵妄通常是由一种或多种因素引起的。促成因素包括严重或长期疾病以及身体失衡，例如低钠。它也可能是由某些药物、感染疾病、手术、酒精或药物使用或戒断症状引起的。
市场动态
预计主要市场参与企业活性化的研发活动将在预测期内推动全球谵妄管理激动市场的成长。例如，2023年9月11日，製药公司工业株式会社宣布开始中枢神经系统（CNS）抑制剂/催眠药物雷美替胺（Rozerem）的临床试验。 Ramelteon 是一种中枢神经系统抑制剂和催眠药，可给药薄膜衣片或包衣片。
本研究的主要特点
- 该报告深入分析了全球谵妄管理市场的风潮，并提供了以2022年为基准年的预测期（2023-2030年）的市场规模和年复合成长率(CAGR)。
- 它还揭示了各个细分市场的潜在商机，并为该市场说明了一系列有吸引力的投资提案。
- 它还提供了有关市场驱动因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
- 它根据公司亮点、产品系列、主要亮点、绩效和策略等参数，介绍了全球谵妄管理市场兴奋的主要企业。
- 该报告的见解使行销人员和公司负责人能够就未来的产品发布、升级、市场扩张和行销策略做出明智的资讯。
- 令人兴奋的全球谵妄管理市场报告迎合了该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
- 透过用于分析全球谵妄管理市场兴奋的各种策略矩阵，将有助于相关人员做出决策。
目录
第1章调查目的和假设
- 这项研究的目的
- 假设
- 简称
第2章市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第3章市场动态、法规及趋势分析
- 市场动态
- 促进因素
- 抑制因素
- 市场机会
- 影响分析
- 最近的产品核准/发布
- 合併、收购和合作
- 法规场景
- 价格分析
- 主要进展
- PEST分析
- 波特的分析
第4章全球谵妄管理市场活跃－新型冠状病毒感染疾病（COVID-19）影响分析
- 经济影响
- 新型冠状病毒感染疾病（COVID-19）的流行病学
- 对需求和供给的影响
第5章2018-2030 年全球谵妄管理兴奋市场（依药物类型）
- 第一代抗精神病药
- 第二代抗精神病药
- 苯二氮平类
第6章谵妄管理的全球兴奋市场（按给药途径），2018-2030 年
- 口服
- 肌肉注射
- 其他的
第7章2018-2030 年全球谵妄管理市场的兴奋程度（依配销通路）
- 医院药房
- 零售药房
- 网路药房
第8章2018-2030 年全球谵妄管理市场的兴奋程度（按地区）
- 北美洲
- 美国
- 加拿大
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲国家
- 亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 其他亚太地区
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 中东
- GCC
- 以色列
- 其他中东地区
- 非洲
- 北非
- 中部非洲
- 南非
第9章竞争形势
- 公司简介
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Mylan NV
- Fresenius Kabi AG
- Novartis AG
- Akorn Incorporated
- Zydus Cadila
- Pfizer, Inc.
- BioXcel Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
- 分析师观点
第10章章
- 参考
- 调查方法
简介目录
Product Code: CMI4430
Global agitation in delirium management market is estimated to be valued at US$ 237.2 Mn in 2023, and is expected to exhibit a CAGR of 4.6% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 237.2 Mn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 4.60% | 2030 Value Projection: | US$ 324.9 Mn |
Delirium is commonly associated with myriad conditions and requires a variety of medications. Early recognition and on-time treatment can help reduce morbidity, length of hospital stay, health care costs, and mortality in patients. According to Marie Curie, a registered organization in the U.K. that provides nursing and hospice care to elderly patients, they have mentioned on their website that many patients develop delirium in the last few days of their lives, which can cause agitation or restlessness. This is sometimes called terminal restlessness or terminal agitation. First-generation antipsychotics are the first choice of treatment for agitation in delirium management patients, followed by second-generation antipsychotics and benzodiazepines. Delirium is a serious change in mental abilities. It results in confused thinking and a lack of awareness of someone's surroundings. The disorder usually comes on fast, within hours or a few days. Delirium can often be traced to one or more factors. Factors may include a severe or long illness or an imbalance in the body, such as low sodium. The disorder may also be caused by certain medicines, infection, surgery, or alcohol or drug use or withdrawal.
Market Dynamics
Increasing research and development activities by key market players is expected to drive the global agitation in delirium management market growth over the forecast period. For instance, on September 11, 2023, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced that they had started a clinical trial for Ramelteon (Rozerem), a central nervous system (CNS) depressant and hypnotic. It is formulated as film-coated tablets and coated tablets for oral route of administration.
Key features of the study:
- This report provides an in-depth analysis of the global agitation in delirium management market and provides market size (US$ Mn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global agitation in delirium management market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., BioXcel Therapeutics, Inc., and Takeda Pharmaceutical Company Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global agitation in delirium management market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global agitation in delirium management market
Detailed Segmentation:
- By Drug Type:
- First-generation Antipsychotics
- Second-generation Antipsychotics
- Benzodiazepines
- By Route of Administration:
- Oral
- Intramuscular
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Glenmark Pharmaceuticals Limited
- Mylan N.V.
- Fresenius Kabi AG
- Novartis AG
- Akorn Incorporated
- Zydus Cadila
- Pfizer, Inc.
- BioXcel Therapeutics, Inc.
- Takeda Pharmaceutical Company Limited
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Approvals/Launches
- Mergers, Acquisitions, and Collaborations
- Regulatory Scenario
- Pricing Analysis
- Key Developments
- PEST Analysis
- Porter's Analysis
4. Global Agitation in Delirium Management Market - COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Agitation in Delirium Management Market, By Drug Type, 2018- 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- First-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018- 2030, (US$ Mn)
- Segment Trends
- Second-generation Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Benzodiazepines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
6. Global Agitation in Delirium Management Market, By Route of Administration, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Intramuscular
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Segment Trends
7. Global Agitation in Delirium Management Market, By Distribution Channel, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Mn)
8. Global Agitation in Delirium Management Market, By Region, 2018 - 2030, (US$ Mn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018 -2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 -2030, (US$ Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Sun Pharmaceutical Industries Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Glenmark Pharmaceuticals Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Fresenius Kabi AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Novartis AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Akorn Incorporated
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Zydus Cadila
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- BioXcel Therapeutics, Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- Analysts' Views
10. Section
- References
- Research Methodology
- About us and Sales Contact
